Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should KnowZacks Investment Research • 03/07/24
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual MeetingGlobeNewsWire • 03/05/24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023GlobeNewsWire • 02/28/24
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of MelanomaGlobeNewsWire • 11/09/23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023GlobeNewsWire • 11/07/23
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 09/27/23
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle PlatformPRNewsWire • 09/11/23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023GlobeNewsWire • 08/08/23
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/07/23
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/05/23
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023GlobeNewsWire • 05/04/23
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/01/23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022GlobeNewsWire • 02/28/23
Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive OfficerGlobeNewsWire • 12/15/22